Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer antibodies - Oruka Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: anticancer antibodies - Oruka Therapeutics

Alternative Names: IREM-1-antagonists; NTB-A; NTB-A-antagonists; NU 10458; NU 2444; NUVO 13759; NUVO 14453; NUVO 16587; NUVO 17289; NUVO 18778; NUVO 18832; NUVO 2788

Latest Information Update: 03 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer Oruka Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin-like molecule-1 protein inhibitors; CD150 antigen inhibitors; CD300LF protein antagonists; Complement activation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 29 Aug 2024 ARCA biopharma Inc has merged with Oruka Therapeutics to form Oruka Therapeutics
  • 04 Oct 2012 Discontinued - Preclinical for Leukaemia in USA (Parenteral)
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top